Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

BACKGROUND: We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients with advanced melanoma in a phase II clinical trial. The response of individual l...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Kaufman, Howard L., Amatruda, Thomas, Reid, Tony, Gonzalez, Rene, Glaspy, John, Whitman, Eric, Harrington, Kevin, Nemunaitis, John, Zloza, Andrew, Wolf, Michael, Senzer, Neil N.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4791835/
https://ncbi.nlm.nih.gov/pubmed/26981242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0116-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars